Additionally, several studies have shown that patients who achieve pathological compete response (pCR) after NAC have a better prognosis than those with residual disease in human epidermal growth factor receptor 2 (HER2)-positive breast cancer and triple-negative breast cancer (TNBC) [5–7], indicating that NAC could offer prognostic information. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.